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Alfacalcidol and paricalcitol are vitamin D analogs used for
the treatment of secondary hyperparathyroidism in patients
with chronic kidney disease, but have known dose-
dependent side effects that cause hypercalcemia and
hyperphosphatemia. In this investigator-initiated multicenter
randomized clinical trial, we originally intended two
crossover study periods with a washout interval in 86 chronic
hemodialysis patients. These patients received increasing
intravenous doses of either alfacalcidol or paricalcitol for
16 weeks, until parathyroid hormone was adequately
suppressed or calcium or phosphate levels reached an upper
threshold. Unfortunately, due to a period effect, only the
initial 16-week intervention period for 80 patients was
statistically analyzed. The proportion of patients achieving
a 30% decrease in parathyroid hormone levels over the last
four weeks of study was statistically indistinguishable
between the two groups. Paricalcitol was more efficient at
correcting low than high baseline parathyroid hormone
levels, whereas alfacalcidol was equally effective at all levels.
There were no differences in the incidence of hypercalcemia
and hyperphosphatemia. Thus, alfacalcidol and paricalcitol
were equally effective in the suppression of secondary
hyperparathyroidism in hemodialysis patients while calcium
and phosphorus were kept in the desired range.
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Patients with chronic kidney disease have increased risk of
cardiovascular disease and mortality compared with patients
with normal renal function.1–3 Epidemiological studies have
found this increased risk to be associated with the
disturbances in the mineral metabolism, including poorer
cardiovascular and mortality outcomes in patients with
elevated calcium and phosphate levels.4–10
Secondary hyperparathyroidism is a common complica-
tion in patients with renal failure and is associated with renal
osteodystrophy,11,12 risk of bone fracture,13 and higher risk of
cardiovascular morbidity and mortality.7,14
Vitamin D analogs are used to treat secondary hyper-
parathyroidism. However, vitamin D analogs increase the
calcium and phosphate levels by increasing the intestinal
calcium and phosphate absorption, as well as increasing
the calcium and phosphate mobilization from the bone.15
To suppress the secondary hyperparathyroidism without
increasing calcium and phosphate, treatment modalities such
as non-calcium-containing phosphate binders, selective
vitamin D analogs, and calcimimetics have been developed.
Alfacalcidol (1a-hydroxyvitamin D3) and paricalcitol
(19-nor-1a,25 dihydroxyvitamin D2) are frequently used
vitamin D analogs, especially in Europe. Alfacalcidol has been
used for treatment of secondary hyperparathyroidism and
renal osteodystrophy since 1978. Paricalcitol was registered in
Denmark in 2004 and was introduced as a less calcemic and
phosphatemic vitamin D analog. In uremic rats,16 paricalcitol
suppressed parathyroid hormone (PTH) levels with less
hypercalcemic and hyperphosphatemic effects than calcitriol
(1a,25 dihydroxyvitamin D3). Until now, no randomized
controlled study addressed possible differences between
alfacalcidol and paricalcitol.17
This investigator-initiated clinical trial compared alfacal-
cidol and paricalcitol. In a crossover study with forced
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titration, we tested whether there is any difference in the
ability of paricalcitol and alfacalcidol to reduce secondary
hyperparathyroidism in hemodialysis patients without
increasing p-calcium and p-phosphate outside the desired
range.
RESULTS
Patient characteristics
Patients were recruited from June 2007 through December
2009. Patients were followed up until the last study visit
(the last patient visit was in October 2010).
Because of the lack of eligible patients, the trial was
stopped early. This decision was taken by the steering
committee. No interim analysis took place. A final inclusion
date was set 3 months ahead, and all investigators made
a final recruitment effort. A total of 86 patients were
randomized, of whom 80 patients completed the first
treatment period and 71 patients completed both treatment
periods (Figures 1 and 2). Demographic characteristics for
randomized and analyzed participants are presented in
Table 1.
Mineral metabolism
Changes in PTH levels, ionized calcium (Ca), and phosphate
(P) for the patients who completed the crossover study are
shown in Figure 3. There was a significant difference between
the baseline mean PTH levels in period 1 and period 2
(552±202 and 453±249 pg/ml, respectively; P¼ 0.01). The
PTH level was significantly higher before beginning of
washout period 1 (317±155 pg/ml) compared with washout
period 2 (219±187 pg/ml; Po0.01). The PTH levels before
and after washout 2 were significantly correlated (0.398;
P¼ 0.001). Only four patients were formerly untreated and
included directly at week 6 (paricalcitol–alfacalcidol: n¼ 3;
and alfacalcidol–paricalcitol: n¼ 1).
Randomized (n=86)
Assessed for eligibility (n=133)
Written informed consent
Excluded after 6 weeks washout  (n=47)
♦ Not meeting inclusion criteria (n=31)
ο Low PTH=27 
ο High phosphate=4
♦ Exclusion (n=8)
ο Malignancy=7
ο One-year survival not expected=1
♦ Other reasons (n=8)
ο Transplantation=1
ο Death=3
ο Failed to washout=2
ο Withdrawn consent=2
Analyzed
• Crossover (n=34)
• Period 1 (n=38)
Discontinued intervention (n=7) during
• Alfacalcidol (n=3)
ο Withdrawn consent=2
ο Malignancy=1
• Washout period 2 (n=3)
ο Transplantation=1
ο Death=1
ο Withdrawn consent=1
• Paricalcitol (n=1)
ο Withdrawn consent=1
Alfacalcidol–paricalcitol
Allocated to intervention (n=41)
Discontinued intervention (n=8) during
• Paricalcitol (n=3)
ο Transplantation=1
ο Withdrawn consent=2
• Washout period 2 (n=1)
ο Death n=1
• Alfacalcidol (n=4)
ο Transplantation=3
ο Death=1
Paricalcitol–Alfacalcidol
Allocated to intervention (n=45)
Analyzed
• Crossover (n=37)
• Period 1 (n=42)
Allocation
Analysis
Follow-Up
Enrollment
Figure 1 |Participants’ flow through the study. PTH, parathyroid hormone.
Washout 1
weeks 0–6
Alfacalcidol
weeks 28–44
Paricalcitol
weeks 28–44
Paricalcitol
weeks 6–22
Alfacalcidol
weeks 6–22
Washout 2
weeks 22–28
Period 1 Period 2
Figure 2 |Treatment periods and treatment arms.
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A significant period effect was found between period 1
and period 2. Therefore, the crossover data were not
accessible for further analysis. The analysis was performed
for data from period 1 (n¼ 80). As there were no laboratory
data from dropout patients, these were not included in the
analysis.
After 16 weeks of treatment, a 30% decrease in PTH level
during the last 4 weeks was reached in 82 and 93% of
alfacalcidol- and paricalcitol-treated patients, respectively
(P¼ 0.180). A total of 68% and 83% of alfacalcidol-
and paricalcitol-treated patients reached a level of PTH
o300 pg/ml (P¼ 0.188). Success criteria defined as PTH
o300 pg/ml with phosphate o1.8 mmol/l and ionized
calcium o1.30 mmol/l was reached in 18 and 31% of
alfacalcidol- and paricalcitol-treated patients, respectively
(P¼ 0.301).
Baseline measurements, mean measurements of the last 4
weeks of treatment, and comparisons of changes for primary
and secondary end points are presented in Table 2.
When analyzing the PTH changes with the baseline values
as covariates, there was a significant interaction between the
effect of baseline PTH level and the effect of treatment
(P¼ 0.012). The effect of the interaction is shown in Figure 4,
where mean measurements of the last 4 weeks are plotted
against baseline PTH levels. The difference between treat-
ments in patients with high versus low baseline PTH levels
is illustrated in Figure 5. The analysis was also performed
for period 2 in the 71 patients who fulfilled the study and
the same interaction was found, although not statistically
significant (P¼ 0.10).
Overall, the mean PTH levels decreased faster in the
paricalcitol group. A 30% decrease in mean PTH level was
reached after 4 weeks of treatment in the paricalcitol group
and after 8 weeks of treatment in the alfacalcidol group.
Mean PTH levels were suppressed beneath 300 pg/ml after
6 weeks of treatment in the paricalcitol group and after
12 weeks of alfacalcidol treatment.
The incidence levels of hyperphosphatemia, hyper-
calcemia, and elevated Ca P are described in Table 3.
The median (range) final doses for the last 4 weeks were
as follows: alfacalcidol 5.3 mg/week (0.0–33.0 mg/week), and
paricalcitol 18.1 mg/week (6.8–60.0 mg/week).
Phosphate-binder usage is presented in Table 4. No patient
received magnesium- or aluminum-containing phosphate
binders. No patient entered the use of calcimimetics, nor
were they referred for parathyroidectomy during the study.
Based on the present changes in PTH, calcium and
phosphate levels, in the alfacalcidol group (n¼ 38) and
Table 1 | Baseline demographic and clinical characteristics
All randomized (n=86) Analyzed period 1 (n=80)
Alfacalcidol–paricalcitol
(n=41)
Paricalcitol–alfacalcidol
(n=45)
Alfacalcidol
(n=38)
Paricalcitol
(n=42)
Age (years±s.d.) 63.6±13.7 63.5±15.3 63.7±14.0 63.7±15.8
Gender (male/female (%/%)) 27/14 (66/34) 28/17 (62/38) 25/13 (66/34) 26/16 (62/38)
Race
Caucasian 41 (100%) 44 (97%) 38 (100%) 41 (98%)
Hispanic 0 (0%) 1 (3%) 0 (0%) 1 (2%)
Diabetes 6 (15%) 7 (16%) 6 (16%) 7 (17%)
Time on dialysis (months; median (range)) 38 (3–236) 36 (3–262) 35.5 (3–236) 37.5 (3–240)
Etiology of end-stage kidney disease
Diabetes 5 (12%) 7 (16%) 5 (13%) 7 (17%)
Nephrosclerosis 5 (12%) 8 (18%) 5 (13%) 8 (19%)
Polycystic 7 (17%) 7 (16%) 6 (16%) 6 (14%)
Chronic glomerulonephritis 9 (22%) 7 (15%) 9 (24%) 6 (14%)
Chronic interstitial 3 (8%) 3 (7%) 2 (5%) 2 (5%)
Postrenal 5 (12%) 4 (9%) 4 (11%) 4 (10%)
Unknown 7 (17%) 9 (20%) 7 (19%) 9 (21%)
Previous vitamin D therapy 40 (98%) 43 (96%) 37 (97%) 41 (98%)
Alfacalcidol oral 39 (95%) 39 (87%) 37 (97%) 37 (88%)
Mean dose (mg/week; median (range)) 3.5 (1.5–18.0) 3.5 (0.5–12.0) 3.5 (1.5–18.0) 3.5 (0.5–10.5)
Alfacalcidol intravenous 1 (2%) 1 (2%) 0 (0%) 1 (2%)
Paricalcitol oral 0 (0%) 2 (4%) 0 (0%) 2 (5%)
Cholecalciferol oral 0 (0%) 2 (4%) 0 (0%) 2 (5%)
Ergocalciferol oral 0 (0%) 1 (2%) 0 (0%) 1 (2%)
p-Intact PTH (pg/ml ±s.d.) 566±208 538±190 571±210 528±176
p-Phosphate (mmol/l±s.d.) 1.48±0.27 1.46±0.28 1.49±0.25 1.45±0.28
p-Calcium ionized (mmol/l±s.d.) 1.16±0.07 1.15±0.07 1.15±0.07 1.15±0.07
p-Hemoglobin (mmol/l±s.d.) 7.3±0.76 7.3±0.76 7.3±0.76 7.3±0.77
p-Albumin (g/l±s.d.) 40.5±3.6 40.0±3.8 40.3±3.6 39.7±3.7
p-25 hydroxyvitamin D2+D3 (nmol/l±s.d.) 42.1±21.3 40.5±24.0 41.1±21.2 39.8±24.2
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paricalcitol group (n¼ 42), and on the basis of the results of
the two-tailed test, a¼ 0.05, a power of 33, 86, and 99.6% is
calculated to detect a difference in PTH reduction of 10, 20,
and 30% between groups, respectively. A calcium increase of
5 and 10% is detected with a power of 77.5 and 99.9%,
respectively, and a phosphate increase of 5, 10, and 20% is
detected with a power of 11, 28, and 79%, respectively.
Hemodynamic parameters
The baseline systolic pressure, diastolic pressure, pulse
pressure, and pulse were equal between groups. There was
no change in these parameters during the treatment, and no
difference in changes between groups (Supplementary
Material, Table 3S online).
Safety measures and adverse events
There were no clinical relevant differences in changes in
safety parameters. These are shown in detail in Supplemen-
tary Material, Table 2S online.
During the study, 490 adverse events (AEs) were
registered. There was a higher report of skin-related AEs in
alfacalcidol-treated patients, consisting of various kinds of
complaints. In total 132 of the AEs were considered as a
serious AE, including six deaths. Three patients died during
the primary washout period, before randomization, and two
during the second washout period: three because of
septicemia, one because of herpes simplex virus encephalitis,
and one because of sudden death. One patient receiving
alfacalcidol decided to withdraw from dialysis treatment
during second treatment period, and died from pneumonia.
The remaining 126 serious AEs occurred due to hospitaliza-
tion or prolonged hospitalization.
Six patients withdrew from the study of their own accord.
No patients were withdrawn by the investigators.
The AEs and withdrawals are further specified in
Supplementary Material, Table 1S online).
DISCUSSION
This study is the first randomized clinical trial comparing
alfacalcidol and paricalcitol. Hemodialysis patients with
secondary hyperparathyroidism were treated with alfacalcidol
and paricalcitol under forced titration until PTH were
sufficiently suppressed or calcium and/or phosphate passed
a maximal threshold. In the uncorrected analysis, there were
no statistically significant differences in the ability of the two
compounds to suppress PTH after 16 weeks of treatment,
whereas calcium and phosphate were maintained within the
Figure 3 |Changes in parathyroid hormone (PTH), % reduction
in PTH, changes in ionized calcium and phosphate during the
44-week study period. Alfacalcidol–paricalcitol (AP, m), n¼ 34.
Paricalcitol–alfacalcidol (PA, &), n¼ 37. Weeks 0–6 and weeks
22–28 were washout periods. Comparison between groups;
*Po0.05, unpaired t-test. Comparison with baseline (week 6 in
period 1 and week 28 in period 2); yPo0.05, paired t-test for both
AP and PA group. #Po0.05, paired t-test AP group. Po0.05,
paired t-test PA group.
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desired range. With a sufficient power to detect a 20%
difference in PTH suppression, this indicates that overall
alfacalcidol and paricalcitol are equally effective.
Paricalcitol has, almost exclusively, been compared with
calcitriol in both animal16,18,19 and human20–30 studies. In a
large north American–European (n¼ 263) randomized trial,
Sprague et al.28 compared paricalcitol and calcitriol. Similar
to our study in which the end point was a 30% reduction,
no difference in the proportion of subjects reaching a
PTH suppression of 50% was found. Sprague et al. found a
reduced incidence of sustained hypercalcemia and elevated
Ca P in the paricalcitol-treated group. In contrast, we did
not find any difference in the incidence of hypercalcemia,
hyperphosphatemia, or elevated Ca P between alfacalcidol
and paricalcitol. The results from the comparative studies
of paricalcitol and calcitriol have been applied to alfacalcidol,
classically considered as a prohormone, exerting its effects
after 25 hydroxylations in the liver into calcitriol.31 The
differences between the present study and the study by
Sprague et al. may be explained by an innate effect of
alfacalcidol, which does not induce elevated phosphate
and calcium. Indeed, acute intravenous administration of
equal doses of alfacalcidol and calcitriol suppressed PTH to
the same level, whereas the plasma concentrations of
1,25(OH)2vitaminD raised to a lower level after alfacalcidol
than after calcitriol.32 Furthermore a direct suppressive effect
of alfacalcidol on PTH production in bovine parathyroid cells
has been observed.33 Alfacalcidol and calcitriol have been
compared in small long-term studies in hemodialysis
patients.34–36 Alfacalcidol and calcitriol were administered
intravenously by El-Rashaid et al.34 and intermittent orally
by Kiattisunthorn et al.35 Both found equal PTH suppression,
with equal changes in calcium and phosphate levels.
Equal doses of both drugs were applied by El-Rashaid
et al., arguing for alfacalcidol being a prodrug to calcitriol.
On the other hand, the oral dose of alfacalcidol in the
study by Kiattisunthorn et al. was half that predicted
from pharmacokinetic studies,32 arguing for a direct effect
of alfacalcidol.
When correcting for baseline PTH level, we found that
alfacalcidol suppressed PTH throughout the entire range of
PTH levels, whereas paricalcitol was more efficient at the
lower PTH levels than at the higher PTH levels. The
differentiated paricalcitol response is in accordance with a
switch study from ordinary calcitriol to scheduled paricalcitol
in hemodialysis patients. The patients with the highest PTH
responded least to paricalcitol treatment and the baseline
PTH level was independently associated with response to
paricalcitol treatment.30 The baseline-independent PTH-
lowering effect was not found in randomized studies
comparing oral paricalcitol with placebo in stages 3–4 CKD
patients, 37 and oral alfacalcidol with calcitriol in hemo-
dialysis patients.35 Other randomized studies examining
paricalcitol or alfacalcidol have used baseline PTH as
covariate, but did not report whether interaction between
baseline and treatment was present.38–40T
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A difference in the PTH response across the range of
baseline PTH may have several possible mechanisms. The
vitamin D analogs may differ in their direct effect on
parathyroid glands and the production of PTH or indirectly
by differences in calcium and phosphate levels. In addition,
FGF23, a recently discovered phosphate-regulating hor-
mone,41 was shown to suppress PTH secretion in rats,
parathyroid rat culture, and bovine parathyroid cells.42,43 It is
unknown whether alfacalcidol and paricalcitol differ in their
induction of the synthesis of FGF23.
Only some of the possible areas in which alfacalcidol and
paricalcitol may differ in their direct effect on the parathyroid
gland have been explored. Alfacalcidol binds to the vitamin D
receptor, with 0.4% of the affinity of calcitriol,44 whereas the
affinity for paricalcitol is 33% of calcitriol.45 This difference
may be compensated by intracellular accumulation of
alfacalcidol. Indeed, paricalcitol has the same affinity for
vitamin D-binding protein as calcitriol, whereas alfacalcidol
has a low affinity for vitamin D-binding protein and may
rapidly be taken up by the parathyroid gland before 25
hydroxylations by the liver.46 Non-genomic actions15 of
vitamin D analogs and actions not involving the vitamin D
receptor47 have been described and may be affected variously
by different analogs. Other issues that remain to be explored
are different conformational changes in VDR when binding,
different interaction with corepressor and co-activators
required for VDR function, different binding to intracellular
proteins, and different induction of catabolic enzymes.46
In comparative studies of paricalcitol and calcitriol, a
decreased calcium mobilization from bone in parathyroi-
dectomized rats,19 decreased intestinal calcium uptake in
hemodialysis patients23 and in normal rats,18 and decreased
Baseline PTH (pg/ml)
1200.001000.00800.00600.00400.00200.00
PT
H
 (p
g m
l–1
) m
ea
n a
fte
r 1
4 a
nd
 16
 w
ee
ks
 of
 tre
atm
en
t 1000.00
800.00
600.00
400.00
200.00
0.00
Paricalcitol
Alfacalcidol
Paricalcitol
Alfacalcidol
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Figure 5 |Changes in parathyroid hormone (PTH), ionized
calcium, phosphate, and vitamin D analog dose during first
treatment period, divided according to the level of PTH at
baseline. Changes separated into low baseline PTH p600 pg/ml
(alfacalcidol, n¼ 24,K; paricalcitol, n¼ 34,J) and high baseline
PTH 4600 pg/ml (alfacalcidol, n¼ 14, ’; paricalcitol, n¼ 8, &).
(a) PTH; (b) ionized calcium; (c) phosphate; (d) vitamin D analog
dose. Alfacalcidol dose is multiplied by 3, because alfacalcidol:
paricalcitol dosing is 1:3. Alfacalcidol, low PTH (white); alfacalcidol,
high PTH (diagonal lines); paricalcitol, low PTH (horizontal lines);
paricalcitol, high PTH (black). Comparison between low PTH
groups; *Po0.05 and high PTH groups; yPo0.05 (unpaired t-test.).
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incidence of hypercalcemia and hyperphosphatemia in
hemodialysis patients28 were found during paricalcitol
treatment. Differences in other treatment modalities could
compensate for differences in calcium and phosphate levels in
the present study. Importantly, the only difference in
phosphate binders was a decreased sevelamer usage in the
alfacalcidol group, arguing for a less hyperphosphatemic
tendency. Changes in urea reduction rate as an indicator of
dialysis dose were equal. Further assessment of dialysis dose
was not performed. We did not carry out registration of
dietary intervention and advice. This could be a bias with
respect to the phosphate level, as the study was unblinded.
The dosing of alfacalcidol:paricalcitol was given in 1:3
ratio, according to the present recommendation, when
switching from calcitriol to paricalcitol.22 This ratio may be
questioned,48 but the forced titration should secure a
sufficient dose increase in both groups.
Paricalcitol decreased PTH faster than alfacalcidol in the
first treatment period. As illustrated in Figures 3 and 5, the
level of ionized calcium was increased at the same time,
which probably explains the different effect on PTH. A non-
equipotent dose titration could be the reason. Whether a
difference of 4 to 6 weeks before reaching the goal has any
clinical importance for the long-term prognosis regarding
bone fracture, and the cardiovascular disease risk associated
with elevated PTH,6,49,50 is not known.
As in earlier interventional studies,29,51 the PTH appar-
ently reached a plateau after 14–16 weeks of treatment.
Prolonging the study period may have led to further PTH
suppression even after 16 months,22 possibly through a
reduction in the parathyroid hyperplasia.
The period effect observed was not due to a pharma-
cological effect of the analogs.32,52 Apparently, a biological
effect persists after 6 weeks washout as the rise in PTH
depends on the degree of the preceding PTH suppression.
Vitamin D treatment upregulates the vitamin D recep-
tors,53,54 and this may make the parathyroid glands more
sensitive to the small amounts of endogenous vitamin D,
withholding the PTH suppression.
In conclusion, this randomized study found alfacalcidol
and paricalcitol to be overall equally effective in suppressing
Table 3 | Incidence of hypercalcemia, hyperphosphatemia,
and elevated CaP product
Number of patients
Alfacalcidol
(n=38; %)
Paricalcitol
(n=42; %) P-value
Hypercalcemia
(ionized calcium 41.30mmol/l)
at least once
21 (55) 24 (57) 0.866
Hypercalcemia
(ionized calcium 41.30mmol/l)
at least two consecutive
measurements
12 (32) 16 (38) 0.542
Hyperphosphatemia
(phosphate X1.80mmol/l)
at least once
29 (76) 29 (69) 0.467
Hyperphosphatemia
(phosphate X1.80mmol/l)
at least two consecutive
measurements
17 (45) 14 (33) 0.296
Elevated Ca P X2.3 (mmol/l)2
at least once
25 (66) 29 (69) 0.756
Elevated Ca P X2.3 (mmol/l)2
at least two consecutive
measurements
14 (37) 16 (38) 0.908
Comparison of proportions between groups by Fisher’s exact test.
Table 4 | Phosphate binder use in treatment groups
Number of patients receiving
phosphate binder
Alfacalcidol (n=38) Paricalcitol (n=42)
Median daily dose, mg (range)
Before
treatment
After 16 weeks
treatment
Before
treatment
After 16 weeks
treatment
Any binder 33 (87%) 34 (89%) 38 (90%) 39 (93%)
Calcium containing 28 (74%)
1500 (540–4000)
26 (68%)
1500 (540–4000)
34 (81%)
1440 (500–4000)
31 (74%)
1440 (500–4800)
Begin or increase 3 (8%) 1 (2%)
Stop or decrease 6 (16%) 6 (14%)
Sevelamer 17 (45%)
2400 (1600–7200)
18 (47%)
4800 (1600–7200)
22 (52%)
4800 (1600–7200)
25 (60%)
4800 (1600–7200)
Begin or increase 6 (16%) 5 (12%)
Stop or decrease 4 (11%)* 0
Lanthanum 5 (13%)
2250 (1500–3000)
8 (21%)
2250 (2250–4500)
7 (17%)
2250 (1500–4500)
7 (17%)
2250 (2250–4500)
Begin or increase 6 (16%) 2 (5%)
Stop or decrease 1 (3%) 0
Comparison between groups and within groups, number of patients receiving phosphate binder treatment; no difference (Po0.05, Fisher’s exact test). No difference between
groups in dose of phosphate binder (Po0.05, Mann–Whitney test). No difference in dose before and after treatment within groups (Po0.05, Wilcoxon signed rank test).
Number of patients who 1: began phosphate binder or increased dose; 2: stopped phosphate binder or decreased dose (*Po0.05, Fisher’s exact test).
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secondary hyperparathyroidism in hemodialysis patients.
No difference in calcium and phosphate increase or episodes
of hypercalcemia or hyperphosphatemia was observed.
Alfacalcidol suppressed hyperparathyroidism independent
of baseline PTH level, whereas paricalcitol was most effective
at the lower PTH levels.
MATERIALS AND METHODS
This was an investigator-initiated, multicenter, block-randomized
(1:1), crossover trial. The study design has been earlier described
and discussed,55 and is briefly summarized. The trial was set to
identify a superiority of paricalcitol compared with alfacalcidol.
The study took place in Danish public hospital dialysis departments.
The study was initiated in 11 departments; one center was
dropped because of poor data quality, and analysis of data from this
center was not possible.
Eligible subjects were 418 years old and were receiving chronic
hemodialysis therapy. After a minimum of 6 weeks washout, with-
out any kind of vitamin D supplement, and sufficiently regulated
p-phosphate (o1.8 mmol/l) and ionized p-calcium (o1.25 mmol/l)
levels, the patients were included if p-PTH was 4350 pg/ml
(37.1 pmol/l). The maximal daily dose of elementary calcium in
phosphate binders was 1600 mg. Calcimimetics were not allowed.
Intervention was carried out as shown in Figure 2 and Table 5.
Alfacalcidol (Etalpha, LEO Pharma A/S, Ballerup, Denmark) and
paricalcitol (Zemplar, Abbott Scandinavia AB, Solna, Sweden) were
given at the end of hemodialysis treatment two or three times a week
depending on the frequency of hemodialysis treatment.
Elevated p-phosphate was treated with calcium-free phosphate
binders, dietary intervention, and re-evaluation of the dialysis dose.
Elevated p-calcium led to dietary intervention and reduction of
calcium-containing phosphate binders. The calcium concentration
of dialysate was fixed to 1.25 mmol/l.
The primary efficacy end point was the proportion of patients
achieving X30% reduction in PTH from baseline until the last
4 weeks of treatment with alfacalcidol or paricalcitol. The secondary
outcomes were changes in ionized p-calcium, p-phosphate,
calcium phosphate product, p-alkaline phosphatase, p-25(OH)
vitamin D, p-1,25(OH)2 vitamin D, blood pressure, pulse, and pulse
pressure from baseline until the end of treatment with alfacalcidol or
paricalcitol, respectively.
p-PTH, ionized p-calcium, and p-phosphate were measured
every second week during the treatment periods; the other
parameters were measured at the beginning and the end of each
treatment period. All laboratory analyses were performed at the
local laboratories of the participating departments. The local assays
for PTH were all second-generation assays: Elecsys 2010 (Roche
Diagnostics GmbH, Mannheim, Germany), Immulite 2000 (Siemens
Healthcare Diagnostics, Llanberis, UK), and Architect (Abbott
Laboratories, Abbott Park, IL).
AEs were registered every second week. The registration
procedure and procedure for classification are described in detail
in Supplementary Material online.
A sample size of 117 was planned.55 The patients were
randomized in blocks of 10, to secure equal distribution in the
two groups in each department. The trialists were aware of the block
size. No stratification was performed. Assignments were enclosed
in sequentially numbered, opaque, sealed envelopes. Envelopes were
opened sequentially and the patient’s initials and identification
number written on the assignment. The patients were enrolled and
treatment assignment ascertained by the primary investigator or a
delegate at each center. The envelopes were generated by the study
coordinator and the allocation list was packed afterward in a sealed,
opaque envelope, and stored by the study coordinator. The study
was an open-label study.
Statistics
Continuous data are described as mean (s.d.), and for differences as
mean (s.e.m.), if normally distributed, and as median (range) if not
normally distributed and for very small groups. Paired t-test for
normally distributed and Wilcoxon test for not normally distributed
data were used for comparing changes before and after treat-
ment within groups. Unpaired t-test for normal distributed and
Mann–Whitney test for not normal distributed data compared
changes between groups. Proportions were compared by using
Fischer’s Exact Test. All tests were two sided. A P-value o0.05 was
considered statistically significant.
The correlation between PTH values before and after washout
2 were described by Pearson’s correlation coefficient, comparing the
mean value with the change in these parameters.56
General linear models and multiple logistic regression models
were used for the analyses of differences between effects of treatment
by alfacalcidol and paricalcitol.
Statistical analysis was performed using SPSS Statistics 17.0
(SPSS, Chicago, IL) software.
The study is in compliance with the Helsinki Declaration
of 1975, revised 1983, and approved by the Danish National
Committee on Biomedical Research Ethics (SJ-27), the Danish
Medicines Agency (EudraCT: 2006-005981-37), Danish Data
Protection Agency (2007-41-0503), and registered in ClinicalTrials.
gov (NCT004695).
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